68.10
Arcellx Inc 주식(ACLX)의 최신 뉴스
FY2026 EPS Estimates for Arcellx Lifted by Leerink Partnrs - Defense World
Squarepoint Ops LLC Sells 4,670 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx FY2029 EPS Forecast Raised by Leerink Partnrs - Defense World
Top NASDAQ Stocks Arcellx’s Role by Kalkine - Kalkine Media
Two Sigma Advisers LP Acquires 1,100 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Millennium Management LLC Raises Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Ameriprise Financial Inc. Sells 945 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
How to Take Advantage of moves in (ACLX) - news.stocktradersdaily.com
Nuveen Asset Management LLC Sells 9,110 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc Holds Annual Stockholders Meeting - TipRanks
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Thinking Of Buying Arcellx Inc (NASDAQ: ACLX) Stock? Here’s What You Need To Know - Stocksregister
Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Business Wire
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Bluefield Daily Telegraph
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday - Benzinga
Baron Discovery Fund Initiated a Position in Arcellx (ACLX) - Insider Monkey
BNP Paribas Financial Markets Makes New $1.53 Million Investment in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity - The Globe and Mail
Mercer Global Advisors Inc. ADV Takes $278,000 Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. Reports Q1 2025 Financial Results - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst - TipRanks
Cantor Fitzgerald Expects Reduced Earnings for Arcellx - Defense World
Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness - simplywall.st
Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating - TipRanks
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise - marketscreener.com
Promising Clinical Trial Results and Safety Profile Support Buy Rating for Arcellx Inc’s Anito-cel Therapy - TipRanks
Arcellx Announces Positive Phase 2 Study Results - TipRanks
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - BioSpace
Arcellx Reports Positive Data From Phase 2 IMMagine-1 Study - Nasdaq
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel - TipRanks
Arcellx, Inc. Announces New Positive Data for Its Immagine-1 Study in Patients with Relapsed And/Or Refractory Multiple Myeloma - marketscreener.com
Arcellx Inc.: Strong Financial Position and Promising Phase 2 Study Outcomes Drive Buy Rating - TipRanks
Here’s Why Arcellx (ACLX) Declined in Q1 - Insider Monkey
Arcellx, Inc. (NASDAQ:ACLX) Receives $109.31 Average Target Price from Brokerages - Defense World
Scotiabank Has Lowered Expectations for Arcellx (NASDAQ:ACLX) Stock Price - Defense World
Piper Sandler Remains a Buy on Arcellx Inc (ACLX) - The Globe and Mail
Arcellx Inc (ACLX) Receives a Buy from Scotiabank - The Globe and Mail
Arcellx First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Needham Sticks to Their Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail
Arcellx (ACLX) Maintains Rating as Price Target is Lowered by Sc - GuruFocus
Arcellx price target lowered to $93 from $133 at Scotiabank - TipRanks
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates - MSN
Promising Potential of Arcellx Inc’s Anito-cel Therapy: A Buy Rating Backed by Positive Study Data and Strategic Trial Enhancements - TipRanks
Arcellx (ACLX): Scotiabank Adjusts Price Target Amid Regulatory Concerns | ACLX Stock News - GuruFocus
Arcellx’s Promising Trial Results and Strategic Partnerships Justify Buy Rating with $121 Target - TipRanks
Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts - TipRanks
Promising Potential of Arcellx Inc’s Anito-cel Program Drives Buy Rating - TipRanks
ARCELLX Earnings Results: $ACLX Reports Quarterly Earnings - Nasdaq
Earnings Flash (ACLX) ARCELLX INC. Reports Q1 Revenue $8.1M, vs. FactSet Est of $19.5M - marketscreener.com
Arcellx Provides First Quarter 2025 Financial Results and Business Highlights - Business Wire
Before Buying Arcellx Inc (NASDAQ: ACLX) Stock, Read This First - Stocksregister
자본화:
|
볼륨(24시간):